These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38000294)

  • 41. Differential
    Lee J; Ammerman N; Agarwal A; Naji M; Li SY; Nuermberger E
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High efficacy of the F-ATP synthase inhibitor TBAJ-5307 against nontuberculous mycobacteria in vitro and in vivo.
    Ragunathan P; Sae-Lao P; Hamela C; Alcaraz M; Krah A; Poh WH; Ern Pee CJ; Hou Lim AY; Rice SA; Pethe K; Bond PJ; Dick T; Kremer L; Bates RW; Grüber G
    J Biol Chem; 2024 Feb; 300(2):105618. PubMed ID: 38176652
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TMC207 becomes bedaquiline, a new anti-TB drug.
    Palomino JC; Martin A
    Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736
    [TBL] [Abstract][Full Text] [Related]  

  • 44. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
    Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
    Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of Bedaquiline, Alone or in Combination with Imipenem, against Mycobacterium abscessus in C3HeB/FeJ Mice.
    Le Moigne V; Raynaud C; Moreau F; Dupont C; Nigou J; Neyrolles O; Kremer L; Herrmann JL
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32253217
    [No Abstract]   [Full Text] [Related]  

  • 46. Acquired resistance of Mycobacterium tuberculosis to bedaquiline.
    Andries K; Villellas C; Coeck N; Thys K; Gevers T; Vranckx L; Lounis N; de Jong BC; Koul A
    PLoS One; 2014; 9(7):e102135. PubMed ID: 25010492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and Testing of Analogs of the Tuberculosis Drug Candidate SQ109 against Bacteria and Protozoa: Identification of Lead Compounds against
    Stampolaki M; Malwal SR; Alvarez-Cabrera N; Gao Z; Moniruzzaman M; Babii SO; Naziris N; Rey-Cibati A; Valladares-Delgado M; Turcu AL; Baek KH; Phan TN; Lee H; Alcaraz M; Watson S; van der Watt M; Coertzen D; Efstathiou N; Chountoulesi M; Shoen CM; Papanastasiou IP; Brea J; Cynamon MH; Birkholtz LM; Kremer L; No JH; Vázquez S; Benaim G; Demetzos C; Zgurskaya HI; Dick T; Oldfield E; Kolocouris AD
    ACS Infect Dis; 2023 Feb; 9(2):342-364. PubMed ID: 36706233
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Active Benzimidazole Derivatives Targeting the MmpL3 Transporter in
    Raynaud C; Daher W; Johansen MD; Roquet-Banères F; Blaise M; Onajole OK; Kozikowski AP; Herrmann JL; Dziadek J; Gobis K; Kremer L
    ACS Infect Dis; 2020 Feb; 6(2):324-337. PubMed ID: 31860799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeted Chromosomal Barcoding Establishes Direct Genotype-Phenotype Associations for Antibiotic Resistance in Mycobacterium abscessus.
    Calvet-Seral J; Crespo-Yuste E; Mathys V; Rodriguez-Villalobos H; Ceyssens PJ; Martin A; Gonzalo-Asensio J
    Microbiol Spectr; 2023 Jun; 11(3):e0534422. PubMed ID: 36988496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atomic solution structure of Mycobacterium abscessus F-ATP synthase subunit ε and identification of Ep1MabF1 as a targeted inhibitor.
    Shin J; Harikishore A; Wong CF; Ragunathan P; Dick T; Grüber G
    FEBS J; 2022 Oct; 289(20):6308-6323. PubMed ID: 35612822
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Mann L; Ganapathy US; Abdelaziz R; Lang M; Zimmerman MD; Dartois V; Dick T; Richter A
    Microbiol Spectr; 2022 Dec; 10(6):e0276022. PubMed ID: 36377951
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural Elements Involved in ATP Hydrolysis Inhibition and ATP Synthesis of Tuberculosis and Nontuberculous Mycobacterial F-ATP Synthase Decipher New Targets for Inhibitors.
    Wong CF; Saw WG; Basak S; Sano M; Ueno H; Kerk HW; Litty D; Ragunathan P; Dick T; Müller V; Noji H; Grüber G
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0105622. PubMed ID: 36445139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus.
    Ganapathy US; Del Río RG; Cacho-Izquierdo M; Ortega F; Lelièvre J; Barros-Aguirre D; Aragaw WW; Zimmerman MD; Lindman M; Dartois V; Gengenbacher M; Dick T
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0151421. PubMed ID: 34606340
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Litvinov V; Makarova M; Kudlay D; Nikolenko N; Mikhailova J
    J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34668850
    [No Abstract]   [Full Text] [Related]  

  • 55. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular mechanistic insights into uncoupling of ion transport from ATP synthesis.
    Nath S
    Biophys Chem; 2018 Nov; 242():15-21. PubMed ID: 30195214
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, Synthesis and Biological Evaluation of Anti-tuberculosis Agents based on Bedaquiline Structure.
    Wu C; Luo J; Wu M; Meng F; Cai Z; Chen Y; Sun T
    Med Chem; 2020; 16(5):703-714. PubMed ID: 31203803
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transcriptional Inhibition of the F
    McNeil MB; Ryburn HWK; Harold LK; Tirados JF; Cook GM
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.
    Chen C; Gardete S; Jansen RS; Shetty A; Dick T; Rhee KY; Dartois V
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463541
    [No Abstract]   [Full Text] [Related]  

  • 60. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.